Sarvis Jamey A, Thompson Ian M
University of Texas Health Science Center, San Antonio, Texas 78229-3900, USA.
Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):271-7. doi: 10.1097/MED.0b013e3282fc7038.
This review provides a description of recent insights into the role of androgens in prostate cancer prevention.
Many studies have elucidated a variety of molecular mechanisms involved in the initiation and progression of prostate cancer with many directly or indirectly related to the androgen signaling pathway. Both well known and novel agents for targeting the androgen pathway are under investigation, though very few are in clinical trials. After a review of recent papers describing these mechanisms, their results and implications were summarized.
Finasteride remains the only agent proven to reduce the risk of prostate cancer, though there are currently two other ongoing phase III trials with vitamin E, selenium, and dutasteride. An enhanced understanding of complex interactions with the androgen pathways is leading to the exploration of additional promising approaches to mitigating the risk of prostate cancer.
本综述阐述了雄激素在前列腺癌预防中作用的最新见解。
许多研究阐明了前列腺癌发生和进展过程中涉及的多种分子机制，其中许多机制直接或间接与雄激素信号通路相关。目前正在研究多种靶向雄激素通路的知名及新型药物，不过进入临床试验阶段的很少。在回顾了描述这些机制的近期论文后，总结了它们的结果及意义。
非那雄胺仍是唯一被证实可降低前列腺癌风险的药物，不过目前还有另外两项关于维生素E、硒和度他雄胺的III期试验正在进行。对与雄激素通路复杂相互作用的深入理解，正促使人们探索其他有前景的降低前列腺癌风险的方法。
